Anti-VEGF in Ophthalmology - Topic Map

Topic Breakdown

1. Mechanism & Pharmacology - VEGF-A biology, drug classes (anti-VEGF-A monoclonals/fusion proteins vs bispecific Ang2/VEGF-A), pharmacokinetics, intravitreal half-life differences between agents
2. Approved Indications ("all uses") - neovascular AMD, diabetic macular edema, proliferative diabetic retinopathy, retinal vein occlusion (BRVO/CRVO), retinopathy of prematurity, myopic and other choroidal neovascularization, neovascular glaucoma (off-label)
3. Drug-by-Drug Profile - bevacizumab (off-label), ranibizumab, aflibercept 2mg/8mg, brolucizumab, faricimab, biosimilars (ranibizumab/aflibercept biosimilars)
4. Landmark Trials by Indication - MARINA/ANCHOR, VIEW 1&2, HARBOR, CATT/IVAN, HAWK/HARRIER, TENAYA/LUCERNE, YOSEMITE/RHINE, PULSAR/PHOTON, DRCR.net Protocols I/T/S/V/AC, CRUISE/BRAVO/GALILEO/COPERNICUS
5. Administration, Regimens & Safety - fixed vs PRN vs treat-and-extend, injection technique, endophthalmitis/IOP/thromboembolic risk, tachyphylaxis
6. Recent Advances & Pipeline (2023-2026) - high-dose aflibercept 8mg durability data, faricimab real-world/extension results (AVONELLE-X), port delivery system (Susvimo), gene therapy (ixoberogene soroparvovec/ADVM-022, RGX-314), anti-FGF2 and other novel targets, biosimilar uptake, AI-guided personalized dosing

Brief Overview

Anti-VEGF in Ophthalmology - Topic Map

Topic Breakdown

1. Mechanism & Pharmacology - VEGF-A biology, drug classes (anti-VEGF-A monoclonals/fusion proteins vs bispecific Ang2/VEGF-A), pharmacokinetics, intravitreal half-life differences between agents
2. Approved Indications ("all uses") - neovascular AMD, diabetic macular edema, proliferative diabetic retinopathy, retinal vein occlusion (BRVO/CRVO), retinopathy of prematurity, myopic and other choroidal neovascularization, neovascular glaucoma (off-label)
3. Drug-by-Drug Profile - bevacizumab (off-label), ranibizumab, aflibercept 2mg/8mg, brolucizumab, faricimab, biosimilars (ranibizumab/aflibercept biosimilars)
4. Landmark Trials by Indication - MARINA/ANCHOR, VIEW 1&2, HARBOR, CATT/IVAN, HAWK/HARRIER, TENAYA/LUCERNE, YOSEMITE/RHINE, PULSAR/PHOTON, DRCR.net Protocols I/T/S/V/AC, CRUISE/BRAVO/GALILEO/COPERNICUS
5. Administration, Regimens & Safety - fixed vs PRN vs treat-and-extend, injection technique, endophthalmitis/IOP/thromboembolic risk, tachyphylaxis
6. Recent Advances & Pipeline (2023-2026) - high-dose aflibercept 8mg durability data, faricimab real-world/extension results (AVONELLE-X), port delivery system (Susvimo), gene therapy (ixoberogene soroparvovec/ADVM-022, RGX-314), anti-FGF2 and other novel targets, biosimilar uptake, AI-guided personalized dosing

Brief Overview

Anti-VEGF Therapy in Ophthalmology - Comprehensive Notes

1. Mechanism of Action

• Retards or reverses new vessel growth
• Reduces vascular leakage and macular edema
• Improves visual prognosis dramatically compared to older laser-based therapy

2. Drug Classes

3. All Approved / Established Uses

4. Landmark Trials by Indication

• nAMD: MARINA, ANCHOR (ranibizumab vs sham/PDT); VIEW 1&2 (aflibercept 2 mg); CATT, IVAN (bevacizumab vs ranibizumab, non-inferiority); HAWK/HARRIER (brolucizumab); TENAYA/LUCERNE (faricimab); PULSAR (aflibercept 8 mg); AVONELLE-X (faricimab 4-year extension - ~80% of patients extended to q12w/q16w intervals).
• DME: DRCR.net Protocol I and T; YOSEMITE/RHINE (faricimab); PHOTON (aflibercept 8 mg).
• PDR: DRCR.net Protocol S.
• RVO: CRUISE, BRAVO (ranibizumab); GALILEO, COPERNICUS (aflibercept).
• ROP: BEAT-ROP.

5. Administration & Safety

• Route: intravitreal injection, standard of care.
• Regimens: fixed dosing, PRN (as-needed), and treat-and-extend (T&E) - most real-world practice uses T&E to balance burden and efficacy.
• Risks: retinal detachment, lens damage, RPE tears, endophthalmitis (rare), sustained IOP elevation, sterile intraocular inflammation (notably higher with brolucizumab, occasionally reported after switching between brolucizumab/faricimab/aflibercept 8mg per recent case reports, e.g. PMID 40671998).
• Anti-VEGF therapy is not associated with increased arterial or venous thromboembolic events at a systemic level, per current evidence - Kanski's, p. 612.

6. Recent Advances (2023-2026) and Ongoing Trials

• Faricimab and aflibercept 8 mg now dominate discussion around extending injection intervals to 12-16 weeks. AAO 2025 data (AVONELLE-X, PULSAR extension) show ~80% of patients on faricimab sustaining q12-16w intervals after 4 years; switching from faricimab to aflibercept 8 mg gives modest anatomic gains in some non-responders but not universal benefit.
• A 2025 Bayesian network meta-analysis (PMID 40993448) and multiple 2025 real-world/comparative studies (PMID 39937692, 40971061, 41197714) are actively comparing aflibercept 8 mg vs. faricimab on efficacy, IOP effects, ocular adverse events, and cost-effectiveness - findings so far show broadly comparable efficacy with some differences in inflammation rates and economics favoring one or the other depending on the study/payer perspective.

• Ixoberogene soroparvovec (ixo-vec, Adverum/Eli Lilly) - AAV2.7m8 vector encoding aflibercept-like protein, intravitreal delivery. Phase 1 OPTIC trial (PMID 38152412) showed sustained anti-VEGF expression over 2 years with an acceptable safety profile when paired with corticosteroid prophylaxis.
• Surabgene lomparvovec (sura-vec, RegenxBio/AbbVie, formerly RGX-314) - AAV8 vector, being studied via both subretinal and suprachoroidal delivery; also in Phase 2/3 for diabetic retinopathy.
• 4D-150 (4D Molecular Therapeutics) - another intravitreal AAV candidate. Across programs, Phase I/II data show 80-94% reductions in anti-VEGF injection burden with maintained vision/anatomy. Topline Phase III data are anticipated Q4 2026 through H2 2027.

• Port Delivery System with ranibizumab (Susvimo) - a refillable intravitreal implant offering continuous ranibizumab release, currently being studied for q24-week refill intervals in patients previously treated with non-ranibizumab agents (Genentech/Roche Phase 3b/4 study).

• Anti-FGF2 therapy - Phase 2 trials (PMID 38036609) in both treatment-naive and anti-VEGF-pretreated nAMD patients, showing proof-of-concept efficacy via a non-VEGF angiogenic pathway.
• Angiopoietin-2 co-targeting (already realized clinically via faricimab).

Evidence Currency Check

Persistent Diabetic Macular Edema (DME): Treatment Approach

Defining "Persistent" DME

Step-Wise Management

• Rule out epiretinal traction/vitreomacular interface abnormality on OCT (surgical, not pharmacologic, problem)
• Check compliance/injection interval adequacy - many "non-responders" were under-treated
• Optimize systemic control: glycemic control (HbA1c), blood pressure, lipid management, and nephropathy/fluid status all influence DME persistence - Goldman-Cecil Medicine, and Kanski's Clinical Ophthalmology, p. 530.

• Continuing the same agent at a shorter interval or switching within the anti-VEGF class (e.g., bevacizumab/ranibizumab to aflibercept) is a reasonable first step; DRCR.net Protocol T showed aflibercept had an anatomic edge in eyes with worse baseline vision, though 5-year outcomes converged across agents - Kanski's, p. 530.
• Switching to faricimab (bispecific anti-VEGF-A/anti-Ang-2) is now well-supported for prior anti-VEGF non-responders. A 2025 systematic review/meta-analysis specifically on switching to faricimab for persistent DME (PMID 40571775) found improved anatomic outcomes (reduced CST) after switch from other anti-VEGF agents, consistent with YOSEMITE/RHINE 2-year data showing extended durability and strong drying effect via the dual VEGF-A/Ang-2 mechanism.

• Dexamethasone intravitreal implant (Ozurdex) - a 3-year randomized sham-controlled trial (Boyer et al., cited in Wills Eye Manual) established efficacy; a 2026 narrative review specifically supports early switch to dexamethasone implant in anti-VEGF poor-responders, showing better anatomic and visual outcomes than continuing a failing anti-VEGF regimen.
• Fluocinolone acetonide implant (Iluvien) - longer-acting option (up to 3 years), typically second/later-line.
• Triamcinolone acetonide - shorter-acting, useful for pregnant patients with diabetic maculopathy where anti-VEGF is contraindicated (teratogenicity risk) - Kanski's, p. 530 tip.
• A 2024 systematic review comparing steroids vs anti-VEGF (PMID 38586457) and a 2023 meta-analysis (PMID 36272716) both confirm steroids are an effective alternative/adjunct in DME, with the trade-off of higher rates of cataract progression and IOP elevation - so patient selection (pseudophakic eyes, no glaucoma) matters.
• Emerging RCT data (2025, PMID 40576850) supports early combination therapy - conbercept (anti-VEGF) plus dexamethasone implant given together upfront - showing better outcomes than sequential treatment in some patients, suggesting combination-first strategies may reduce the "persistent" category altogether.

• Topical NSAIDs (e.g., bromfenac) as adjunct to intravitreal ranibizumab showed benefit in a 2023 RCT (PMID 37083870).
• Focal/grid laser remains a reasonable adjunct for extrafoveal persistent leakage, deferred at least 6 months after anti-VEGF initiation per DRCR.net Protocol I, and still useful for non-center-involved or focal microaneurysmal leakage components.

• Pars plana vitrectomy with membrane peeling for cases with vitreomacular traction or epiretinal membrane contributing to persistent thickening - these eyes will not respond to any pharmacologic escalation.

Practical Algorithm

1. Confirm adequate anti-VEGF loading and rule out traction on OCT.
2. Optimize systemic risk factors.
3. If still non-responding after 3-6 injections: switch anti-VEGF class (consider faricimab) OR switch to intravitreal steroid (dexamethasone implant), especially if pseudophakic.
4. Reassess at 3 months; consider combination anti-VEGF + steroid if partial response.
5. If tractional component identified at any point: refer for vitrectomy.
6. Reserve fluocinolone implant for chronic recurrent cases needing longer duration control.

Evidence Currency Note

Intravitreal Implants in Ophthalmology - Notes with Clinical Trials

1. Rationale

2. Corticosteroid Implants

a) Dexamethasone intravitreal implant (Ozurdex, 0.7 mg biodegradable PLGA rod)

• Mechanism: Biodegradable copolymer releasing dexamethasone over ~3-6 months.
• Indications: Macular edema from retinal vein occlusion (RVO), diabetic macular edema (DME), non-infectious posterior segment uveitis.
• Key trial - GENEVA trial: Established that a single Ozurdex implant produces substantial visual and anatomical improvement within the first 2 months in RVO-related macular edema - Kanski's Clinical Ophthalmology, 10th ed., p. 997.
• Use in DME: Recommended as an alternative when there are contraindications to anti-VEGF, or added/switched to after persistent DME despite anti-VEGF monotherapy for 6 months - Kanski's, p. 394-399.
• Recent evidence (2024-2025):
  • A 2024 systematic review (PMID 39678032) confirmed long-term efficacy and safety of dexamethasone implant in RVO, with recurrent treatment needed roughly every 4-6 months.
  • A 2025 meta-analysis (PMID 40601878) compared efficacy in vitrectomized vs non-vitrectomized eyes, finding vitrectomized eyes have faster drug clearance and shorter duration of effect, requiring more frequent re-implantation.
  • A 2026 narrative review supports early switching to dexamethasone implant in DME patients who respond poorly to anti-VEGF, rather than delayed rescue.
• Adverse effects: Cataract progression (in phakic eyes), IOP elevation (~20-30% of patients, usually controllable with topical drops).

b) Fluocinolone acetonide implants (longer-acting, non-biodegradable)

• Iluvien (0.19 mg): Approved for DME; releases drug over up to 36 months.
  • NEW DAY trial (results published 2025-2026, ANI Pharmaceuticals): evaluated Iluvien in DME patients previously treated with corticosteroids without significant IOP rise - reinforces its role as an option after steroid-responsiveness has been established with a shorter-acting agent first.
• Retisert (0.59 mg): Surgically implanted (sutured to sclera), used for chronic non-infectious posterior uveitis; longstanding data (including 7-year outcomes) show sustained efficacy in intermediate/posterior/panuveitis.
• Yutiq (0.18 mg): Injectable (non-surgical) fluocinolone implant for chronic non-infectious posterior segment uveitis; a study sponsor (EyePoint) has an active 2026 trial evaluating Yutiq maintenance in patients who previously responded to steroid therapy.
• Trade-off across all fluocinolone implants: Very high rates of cataract formation and need for IOP-lowering therapy/surgery over their multi-year duration, so patient selection (pseudophakic, no pre-existing glaucoma) is important.

3. Antiviral Implant

Ganciclovir intravitreal implant (Vitrasert - largely historical)

• Provided sustained local ganciclovir release for CMV retinitis, effective for ocular disease but does not treat systemic CMV - Washington Manual of Medical Therapeutics.
• Now largely superseded by systemic valganciclovir given comparable efficacy without needing implant surgery, but the implant remains relevant in refractory/immune-recovery-limited cases.

4. Anti-VEGF / Biologic Sustained-Delivery Devices

Port Delivery System with ranibizumab (Susvimo)

• A surgically implanted, refillable reservoir providing continuous ranibizumab release for nAMD, refilled roughly every 6 months.
• Active ongoing trial: a Phase 3b/4 study (Genentech/Roche) is assessing PDS Q24W refill in nAMD patients previously treated with non-ranibizumab anti-VEGF agents.
• Earlier trial: BURGUNDY (Roche/Genentech) - Phase I safety/tolerability/PK study of sustained delivery from the port system, including a novel molecule RO7250284.

Emerging non-biodegradable/biodegradable implants in active trials (2025-2026 pipeline)

• AR-14034 (Alcon) - Sustained-release implant compared head-to-head against intravitreal anti-VEGF in a Phase 1/2 dose-escalation trial (NOVA/NOVA STAGE 2) for nAMD.
• EC-104 (Eclipse Life Sciences) - Intravitreal implant for DME, being studied in the BETTIS-1 trial.
• EYC-0305 (Eyconis) - Phase 1b/2a OVERTURE trial for nAMD, dosed intravitreally every 24 weeks.
• EYE103/EYE201 (Eyebiotech/MK-8748) - Phase 2 studies (Super Tuscan, MALBEC) for nAMD and RVO-associated macular edema.

5. Comparative Note: Steroid vs Anti-VEGF Implants

6. Special Contexts

• Traumatic proliferative vitreoretinopathy: intravitreal triamcinolone (not a true long-acting implant, but sustained local steroid effect) shown in a 2024 RCT (PMID 38041678) to reduce PVR recurrence when used early after trauma.
• Proliferative vitreoretinopathy (non-traumatic): intravitreal infliximab studied in the FIXER Phase II RCT (PMID 38823559) - not yet an implant formulation but relevant to the biologic-implant pipeline.
• Retinoblastoma: intravitreal chemotherapy (melphalan) reviewed for safety (2024 systematic review, PMID 38897313) - injection-based, not implant, but relevant to the broader intravitreal drug-delivery landscape in ophthalmology.

Summary Table

Evidence Currency Note

Microincisional Vitrectomy Surgery (MIVS) - PG Ophthalmology Exam Notes

1. Definition

2. Historical Evolution

• 20-gauge (0.9 mm): Conventional standard since the 1970s; requires conjunctival dissection, sutured sclerotomies.
• 25-gauge: Introduced by Fujii et al. (2002) - first true sutureless transconjunctival system.
• 23-gauge: Eckardt (2005) - intermediate gauge combining smaller incision with better instrument rigidity/fluidics than 25G at the time.
• 27-gauge: Oshima et al. (2010) described the first 27-gauge instrument system for transconjunctival MIVS (cited over 400 times) - now the smallest clinically used gauge, refined further with dual-blade high-speed cutters and stiffer shaft materials to reduce flexibility-related limitations.

3. Instrumentation

• Self-retaining cannulas inserted via a beveled/angled (oblique) trocar to create a self-sealing scleral tunnel, avoiding sutures in most cases.
• Angled (two-step) sclerotomy entry technique reduces postoperative hypotony and wound leakage compared to straight entry.

• Inner guillotine blade oscillating at high speed - conventional systems 1500 cpm, modern "ultra-high-speed" cutters up to 5000-7500 cpm (some newer dual-blade/dual-pneumatic systems exceed this).
• Higher cutting speed = smaller "bite" per cut = reduced vitreoretinal traction during core and peripheral vitrectomy, improving safety near mobile/detached retina - Kanski's, p. 708.
• A 2025 RCT directly comparing 20,000 vs 10,000 cuts-per-minute with a 27G cutter in rhegmatogenous retinal detachment surgery (PMID 39849295) assessed efficiency and safety differences at these newer ultra-high speeds.

• Fiberoptic light pipe; xenon and mercury-vapor sources now match/exceed 20G brightness while filtering phototoxic UV/blue light.
• Chandelier illumination: self-retaining light source freeing both surgeon hands for true bimanual surgery; dual-chandelier systems eliminate instrument shadowing.

4. Advantages of MIVS over 20-Gauge

• Shorter operating time
• Less conjunctival/scleral trauma and scarring (important for patients needing future glaucoma surgery)
• Faster postoperative visual rehabilitation and reduced postoperative inflammation/pain
• Reduced induced astigmatism
• Comparable operative success rates to 20-gauge - early concerns about increased endophthalmitis risk with smaller gauges have not been substantiated in outcome data - Kanski's, p. 708

5. Disadvantages / Limitations

• Increased instrument flexibility (especially 25G/27G) can reduce maneuverability and cutting efficiency for very dense fibrovascular tissue
• Slower fluidics/aspiration in smaller-gauge systems (mitigated by improved pump technology)
• Risk of hypotony or wound leak if sclerotomies not self-sealing (more likely with 23G than 25/27G due to larger residual defect if angled entry not performed correctly)
• Learning curve for trocar placement and bimanual chandelier-assisted technique

6. Indications for Pars Plana Vitrectomy (applicable to MIVS)

• Non-clearing vitreous hemorrhage (diabetic retinopathy most common)
• Tractional retinal detachment threatening or involving the macula (urgent)
• Combined tractional-rhegmatogenous retinal detachment (urgent)
• Dense premacular (retrohyaloid) hemorrhage with risk of fibrovascular scaffold formation
• Anterior segment neovascularization/media opacity precluding fundus view for PRP
• Epiretinal membrane, macular hole, vitreomacular traction syndrome
• Complicated rhegmatogenous retinal detachment (PVR, giant retinal tear)
• Endophthalmitis (therapeutic vitrectomy)
• Dropped nucleus/IOL fragments after cataract surgery
• Retinal biopsy / intraocular tumor management
• Diabetic macular edema as adjunct to anti-VEGF (see VIDEO trial below)

7. Basic Surgical Technique

1. Peribulbar/retrobulbar or general anesthesia
2. Mark sclerotomy sites: typically 3 ports at pars plana, 3.5-4 mm from limbus (phakic) or 3-3.5 mm (pseudophakic/aphakic)
3. Angled trocar insertion (biplanar, ~30-degree angle then vertical) to create self-sealing tunnel - critical step in sutureless MIVS
4. Insert infusion cannula (inferotemporal), confirm placement in vitreous cavity before starting infusion
5. Insert light pipe (or chandelier) and cutter through remaining two ports
6. Core vitrectomy, induction of posterior vitreous detachment if not already present
7. Peripheral vitreous shaving with scleral indentation as needed
8. Address underlying pathology (membrane peel, laser, tamponade)
9. Fluid-air/fluid-gas exchange or silicone oil fill as indicated
10. Cannula removal with scleral massage; sutures placed only if wound leak persists (uncommon with correctly angled entries)

8. Tamponading Agents (relevant to MIVS as adjunct)

• Expanding gases: SF6 (doubles volume, absorbs in ~2 weeks), C3F8 (quadruples volume, lasts ~8 weeks) - used with postoperative positioning to maximize tamponade effect at the break
• Silicone oil - for complex/recurrent RD, PVR

9. Complications

• Hypotony (higher risk with poor sclerotomy construction)
• Wound leak requiring suture
• Endophthalmitis (rate not significantly different from 20G despite initial concern)
• Retinal breaks/iatrogenic retinal tears at sclerotomy sites or during core vitrectomy
• Cataract progression (especially with gas tamponade)
• Choroidal detachment, suprachoroidal hemorrhage (rare)

10. Comparative Trial Data (Gauge-to-Gauge)

• 25G vs 27G - a large prospective RCT (PMID 38237087, Retina 2024) compared 25-gauge and 27-gauge vitrectomy across vitreoretinal diseases; both are effective with largely comparable safety, though 27G may offer marginal advantages in wound integrity and postoperative comfort.
• 27G beveled-tip vs 25G flat-tip in proliferative diabetic retinopathy - RCT (PMID 38087284, 2023) found differences in postoperative hemorrhage/complication rates between tip designs, relevant to instrument selection in high-risk diabetic cases.
• Small-gauge vitrectomy ± anti-VEGF pretreatment for PDR - systematic review/meta-analysis (PMID 36972566) supports pretreatment reducing intraoperative bleeding and iatrogenic retinal breaks.

11. Recent Advances (2023-2026)

• Ultra-high-speed cutters (up to 20,000 cpm dual-blade systems) - 2025 RCT (PMID 39849295) shows evolving evidence on whether further speed increases meaningfully improve safety/efficiency in RRD surgery over already-fast 10,000 cpm systems.
• Heads-up 3D visualization systems (e.g., NGENUITY-type platforms) - a 2024 study (PMID 38237080) objectively quantified depth-of-field advantages of 3D surgical video systems in macular surgery, and a 2025 pilot RCT (PMID 40407110) compared minimal heads-up versus standard illumination during 27G PPV for epiretinal membrane, assessing retinal function/macular structure outcomes.
• Vitrectomy as adjunct to anti-VEGF for DME - the VIDEO trial (PMID 39115867, JAMA Ophthalmology 2024) - a multicenter RCT testing vitrectomy added to treat-and-extend anti-VEGF for diabetic macular edema, informing whether surgical intervention benefits eyes with a vitreomacular traction component of persistent DME.
• Telemedicine-based postoperative follow-up protocols after MIVS - prospective RCT (PMID 40260705, 2025) evaluating remote postoperative monitoring feasibility, reflecting a broader shift toward reduced in-person follow-up burden after minimally invasive surgery.
• 27G wide-angle viewing + flute needle for internal SRF drainage during combined scleral buckle procedures - RCT (PMID 40317397, 2025) shows small-gauge instrumentation increasingly integrated even into buckle-based (non-vitrectomy-primary) retinal detachment repair.

Exam-Style Summary Table

Key Exam Points to Remember

1. MIVS = transconjunctival + sutureless + small-gauge (23/25/27G) pars plana vitrectomy.
2. Angled (biplanar) sclerotomy entry is the key technical step enabling self-sealing wounds.
3. Endophthalmitis risk with MIVS is not significantly higher than 20-gauge despite early theoretical concerns - important exam pitfall.
4. Chandelier illumination enables bimanual surgery - a frequently tested concept.
5. Faster cutter speeds reduce vitreoretinal traction, a key safety principle in modern vitrectomy.
6. DRCR.net Protocol AB and the VIDEO trial are the two most citable recent RCTs linking vitrectomy to diabetic retinal disease management in an exam context.

Retinopathy of Prematurity (ROP): Recent Screening Guidelines, Treatment Advances, and Role of AI

1. Background

2. Classification - ICROP3 (2021, Third Edition)

• Zones (I, II, III) - concentric zones centered on the disc; zone I = posterior pole (radius = 2x disc-to-macula distance); zone II extends to the nasal ora serrata; zone III is the residual temporal crescent. A "notch" describes a 1-2 clock-hour posterior incursion into a more posterior zone.
• Staging (1-5) - stage 1 (demarcation line), stage 2 (ridge), stage 3 (extraretinal fibrovascular proliferation), stage 4 (partial retinal detachment), stage 5 (total retinal detachment).
• Plus disease - vascular dilation and tortuosity of posterior pole vessels indicating increased disease activity; ICROP3 added a formally recognized "pre-plus disease" intermediate category.
• Aggressive posterior ROP (AP-ROP) - a rapidly progressive form typically in zone I/posterior zone II, refined terminology in ICROP3 (previously "AP-ROP" now more precisely characterized).

3. Recent Screening Guideline Updates

• Infants ≤27 weeks' gestation: first screening at 31 weeks postmenstrual age
• Infants ≥28 weeks' gestation: first screening at 4 weeks chronologic age
• Infants <25 weeks' gestation: consider earlier screening at 6 weeks chronologic age (even before 31 weeks PMA) if comorbidities suggest high risk of AP-ROP
• General screening threshold: birth ≤30 weeks' gestation OR birth weight <1500 g, or unstable clinical course with cardiorespiratory support even if born later - Harriet Lane Handbook, 23rd ed., p. 664-665.

• A trial of speculum-free screening using a proparacaine-soaked cotton swab (PMID 40725872) found it a viable, less traumatic alternative to standard eyelid speculum for fundus exams.
• The MyMiROPS RCT (PMID 39724200, JAMA Ophthalmology 2025) established efficacy/safety of mydriatic microdrops (lower-volume phenylephrine/tropicamide) versus standard drops, reducing systemic drug exposure in this vulnerable population.
• Growing interest in serum biomarkers (e.g., IGF-1, CRP) as adjuncts to clinical screening criteria - a 2025 meta-analysis (PMID 41053373) and 2024 systematic review (PMID 38571701) evaluated biomarker utility, though these remain investigational adjuncts rather than replacements for dilated exam.

4. Advances in Treatment

• BEAT-ROP trial (Bevacizumab Eliminates the Angiogenic Threat of ROP) - the landmark study that changed practice, showing intravitreal bevacizumab superior to laser for zone I stage 3+ disease.
• Aflibercept - FIREFLEYE program:
  • FIREFLEYE (Phase 3 RCT) (PMID 38200320) established systemic pharmacokinetic/exposure data and non-inferiority of intravitreal aflibercept versus laser.
  • FIREFLEYE next (PMID 38687481, JAMA Network Open 2024) - 2-year efficacy/safety outcomes showing sustained benefit of aflibercept over laser therapy.
  • 3-year outcomes (PMID 41505377, 2026) extending follow-up further, reinforcing durability of anti-VEGF treatment effect.
  • A 2025 review (PMID 38730278) cautions that despite promising trial data, "more research" is needed on aflibercept dosing, systemic absorption, and long-term neurodevelopmental safety in this population.
• Comparative agent studies: retrospective comparisons of ranibizumab vs aflibercept (PMID 40600582, PMID 39368879) and conbercept vs aflibercept (PMID 39871372) are examining reactivation rates and angiographic outcomes - reactivation after anti-VEGF (requiring re-treatment or rescue laser) remains a key clinical concern distinguishing anti-VEGF from laser, which has a more definitive single-treatment effect.

5. Role of AI in ROP Screening

• i-ROP Deep Learning (i-ROP-DL) system - integrates two convolutional neural networks (CNNs) for retinal vessel segmentation and classification, showing accuracy comparable to expert human graders in detecting plus disease - one of the most validated AI systems in this space.
• Smartphone-based AI screening in low-resource settings - a 2025 study (PMID/JAMA Network Open, Ortiz et al.) demonstrated that machine learning algorithms applied to smartphone-captured retinal images can expand ROP screening access, allowing lightly trained personnel (not pediatric ophthalmologists) to perform screening - directly addressing the global shortage of trained ROP specialists.
• Image-analysis-based machine learning meta-analysis (PMID 38237772, Ophthalmology Retina 2024) pooled diagnostic accuracy data across ML models for ROP detection/classification, supporting good discriminative performance (high AUC) but noting heterogeneity across datasets and camera systems.
• Cochrane systematic review protocol (PMID 41055082, registered 2025) has been formally initiated to rigorously assess AI-based algorithm diagnostic performance against clinical reference standards, with planned subgroup analysis by ethnicity, input data type (image-only vs. clinical variables vs. combined), CNN vs. DNN architecture, and camera/scanner type (RetCam, Forus, Phoenix ICON). This is a protocol only - definitive pooled results are not yet published, so current AI accuracy claims should be treated as promising but not yet Cochrane-validated.
• Training and education implications - a 2026 systematic review (PMID 40541843) examined how ROP training/education (including telemedicine-supported models) is evolving alongside AI tools, suggesting AI may also serve an educational/triage role for trainees and remote screeners rather than purely autonomous diagnosis.

Evidence Currency Note

Persistent Epithelial Defect (PED): Surgical Management

1. Definition

2. Principle of Stepwise Escalation

3. Surgical / Procedural Options (in escalating order)

• Protects the healing epithelium from lid friction/blink trauma, often combined with tissue glue for small perforations - Kanski's, Fig. 7.6A.
• First-line "surgical" adjunct before more invasive options; can be combined with punctal occlusion to preserve tear film.

• Used under a bandage contact lens for thinning/impending perforation, or for small (<1-2 mm) frank perforations, sealing the defect and allowing epithelium to migrate over it - Kanski's, Fig. 7.6D.

• Temporary (suture-based) or permanent lid closure reduces the exposed corneal surface area and blink-related shear trauma, promoting healing in neurotrophic or exposure-related PEDs - Kanski's, Fig. 7.6B.
• Chemodenervation ptosis (botulinum toxin-induced temporary tarsorrhaphy) is a reversible, less disfiguring alternative achieving a similar protective effect via pharmacologic ptosis.

• Amniotic membrane provides a basement-membrane scaffold rich in anti-inflammatory and anti-scarring growth factors, promoting epithelialization; can be used as a patch (temporary overlay) or graft (sutured/glued directly over the defect) - Kanski's, Fig. 7.6C.
• A 2025 systematic review specifically on AMT for PEDs following infective corneal ulcers/keratitis (PMID 39257085) supports efficacy in promoting closure and improving visual outcomes, though effect size varies by underlying etiology and defect chronicity.
• Layered (multilayer) amniotic membrane grafting is used for larger, deeper defects with associated stromal thinning, per recent reviews of neurotrophic keratopathy management.

• A partial or total conjunctival flap (Gundersen flap) covers the defect with vascularized tissue, useful for severe, non-healing defects, especially when vision potential is already limited or as a bridge to future keratoplasty.

• Preserves tear film volume over the ocular surface; a relatively minor procedural adjunct rather than a definitive surgical solution but frequently combined with the above.

• An emerging surgical option for neurotrophic keratopathy-driven PEDs: sensory nerve transfer (typically from the contralateral supratrochlear/supraorbital nerve, using direct or nerve-graft-interposition technique) to restore corneal innervation and reverse the underlying neurotrophic deficit rather than just protecting the surface.
• Positioned as a durable option for patients with anesthetic/hypoesthetic corneas rather than a temporizing measure - increasingly discussed in recent reviews (2025) as a key "emerging surgical management" alongside cell-based therapies.

• For PEDs secondary to limbal stem cell deficiency (LSCD - chemical/thermal burns, chronic contact lens wear, aniridia, Stevens-Johnson syndrome), replenishing the limbal stem cell pool (autologous or allograft, cultivated limbal epithelial transplantation) is required since amniotic membrane alone cannot correct the underlying stem cell deficit. Amniotic membrane often serves as the scaffold/substrate for these cell-based procedures.

• Prosthetic replacement of the ocular surface ecosystem (PROSE) devices or large-diameter scleral lenses provide continuous fluid reservoir protection and mechanical stability for chronic, refractory PEDs, particularly in severe dry eye or exposure-related disease - a non-surgical but procedural/fitted-device alternative often used alongside or instead of tarsorrhaphy.

• Reserved for cases with corneal perforation, descemetocele, or scarring precluding visual rehabilitation once the epithelial defect has been controlled - typically the last step, not a primary PED treatment.

4. Adjunctive Biologic/Medical Therapies (often paired with surgical steps)

• Autologous serum / platelet-rich plasma tears - deliver endogenous growth factors (EGF, vitamin A, fibronectin) to support epithelial migration; used for refractory cases before/alongside surgical measures.
• Cenegermin (Oxervate) - recombinant human nerve growth factor, FDA-approved for stage 2/3 neurotrophic keratitis; case series (2023) report complete epithelial recovery in moderate-severe neurotrophic keratopathy after an 8-week course, and it is increasingly used to avoid or complement surgical neurotization.
• Topical insulin - a novel, low-cost option shown in a 2025 systematic review (PMID 40381039) and meta-analysis (PMID 40696883) to accelerate healing of PEDs and other ocular surface disorders; a 2023 RCT (PMID 37267451) specifically showed faster healing of iatrogenic corneal epithelial defects after vitreoretinal surgery in diabetics with topical insulin versus artificial tears alone.
• Post-vitrectomy PED is itself a distinct recognized entity - a 2025 narrative review (PMID 39989218) covers risk factors (surgical duration, diabetes, intraoperative epithelial debridement for visualization) and prevention/management strategies specific to this iatrogenic cause.

5. Practical Surgical Algorithm

1. Optimize medical therapy and treat underlying cause (herpetic prophylaxis, lid hygiene, discontinue toxic drops).
2. Bandage contact lens ± punctal plugs.
3. Autologous serum/platelet-rich plasma tears or topical insulin if lubrication alone fails.
4. Amniotic membrane transplantation for defects failing the above after 1-2 weeks.
5. Temporary tarsorrhaphy (suture or botulinum-induced) if exposure/blink trauma is a major contributor, especially in neurotrophic disease.
6. Cenegermin trial for confirmed neurotrophic keratopathy (stage 2/3) as a parallel or alternative track to AMT.
7. Corneal neurotization for confirmed anesthetic cornea with reasonable visual potential and defect recurrence despite the above.
8. Limbal stem cell transplantation if LSCD is the underlying driver.
9. Conjunctival flap or keratoplasty for defects that fail all of the above or when perforation/severe scarring develops.

Evidence Currency Note

Recent Advances in Thyroid Eye Disease (Thyroid Orbitopathy / Graves' Orbitopathy)

1. Background and Classification

2. Established First/Second-Line Management (context for what's new)

• Mild/inactive disease: lubricants, selenium supplementation (in deficient regions), head elevation, eyelid taping, smoking cessation (universal first step).
• Moderate-severe active disease: systemic corticosteroids remain the mainstay - IV methylprednisolone (0.5 g weekly x6 then 0.25 g weekly x6) is superior in tolerability and outcome to oral steroids; IV steroids plus mycophenolate sodium show greater benefit than steroid monotherapy in specialized centers.
• Second-line for steroid-resistant/persistent disease: monoclonal antibody therapy - rituximab, tocilizumab, or teprotumumab - Kanski's, p. 137.
• Low-dose fractionated orbital radiotherapy as an adjunct/alternative, with delayed onset of effect (~6 weeks, maximal by 4 months).

3. Teprotumumab - the Practice-Changing Advance

• A 2025 systematic review/meta-analysis (PMID 39952471) and a second 2025 meta-analysis (PMID 40587732) confirm consistent efficacy for proptosis reduction, diplopia improvement, and CAS reduction in active TED.
• A 2024 meta-analysis specifically addressing long-duration/chronic TED (PMID 39526058) shows teprotumumab retains meaningful proptosis-reducing effect even in longstanding disease, expanding its use beyond the originally studied "active" phase population.
• OPTIC-X/OPTIC-XS long-term data show durability and effectiveness of retreatment in relapsed patients.

• Hearing dysfunction - a 2025 systematic review (PMID 39194388) mapped patterns of teprotumumab-induced ototoxicity (sensorineural hearing loss, tinnitus, autophony), now recognized as a clinically important adverse effect requiring baseline/monitoring audiometry.
• Hyperglycemia - a 2024 analysis of glycemic trends across 3 clinical trials (PMID 38253291, Ophthalmology) characterized glucose elevation patterns, informing screening/monitoring recommendations, particularly in patients with pre-existing diabetes risk.

4. Newly Approved and Late-Stage Pipeline Biologics (2025-2026)

• Veligrotug (VRDN-001, brand LUMVOA) - another anti-IGF-1R monoclonal antibody (Viridian Therapeutics). Positive Phase 3 THRIVE (active TED) and THRIVE-2 (chronic TED) trial results led to FDA approval in June 2026 - the second approved targeted biologic for TED after teprotumumab. Long-term durability data through week 52 have been reported as positive.
• Elegrobart (VRDN-003) - subcutaneous anti-IGF-1R antibody from the same developer, in Phase 3 REVEAL-1 (active TED) and REVEAL-2 (chronic TED) trials, with topline results anticipated in early-to-mid 2026 and a subsequent BLA planned; offers a subcutaneous alternative to infusion-based therapy.
• Batoclimab - an FcRn inhibitor (reduces circulating pathogenic IgG including TSH-receptor antibodies); 2025 data (Kahaly et al.) show it rapidly normalizes thyroid function and improves clinical outcomes in Graves' disease, with TED-specific trials ongoing.
• Linsitinib - an oral small-molecule IGF-1R antagonist (Sling Therapeutics), notable as the first oral (non-biologic, non-infusion) option in active development, currently in Phase 2 study for TED - a potential major convenience advance if positive.
• Lonigutamab - a subcutaneous anti-IGF-1R antibody binding a different epitope than teprotumumab, in Phase 1/2 studies.
• Satralizumab (ENSPRYNG/RG6168) - an IL-6 receptor antagonist (already approved for NMOSD); Genentech's supplemental BLA for TED was accepted with FDA priority review in mid-2026.

5. Other Non-Biologic Advances

• Botulinum toxin for strabismus/eyelid retraction in TED - a 2025 systematic review and meta-analysis (PMID 39700405) supports its role as a minimally invasive option for extraocular muscle imbalance and lid retraction, particularly useful as a bridge or adjunct before definitive strabismus/eyelid surgery.
• Ocular surface-directed therapy - a 2024 systematic review (PMID 38984136) evaluated the range of ocular surface treatments (lubrication, punctal plugs, scleral lenses) specifically in the TED population, reinforcing that surface disease management remains a core parallel need regardless of systemic/biologic therapy choice.
• Comparative effectiveness across disease phases - a 2024 systematic review with meta-analysis (JCEM, PMID 39076015) directly compared treatment modalities (steroids, teprotumumab, other biologics) across initial (active) versus chronic phases of TED, helping refine phase-specific treatment selection and reinforcing that biologics show the largest relative benefit in the active/inflammatory phase.
• Tocilizumab - a 2024 systematic review (PMID 38215463) reaffirms efficacy and safety as a second-line option, particularly for steroid-resistant disease, with a mechanism (IL-6 receptor blockade) distinct from and potentially complementary to IGF-1R-targeted agents.
• Inflammatory biomarkers - a 2024 meta-analysis (PMID 38869186) on neutrophil/monocyte-based inflammatory markers in TED suggests potential future utility for disease activity monitoring and treatment response prediction, though not yet clinically validated for routine use.

6. Surgical Advances (Rehabilitative Phase)

Summary Timeline of Recent Change (2020-2026)

Evidence Currency Note

Recent Advances in Management of Orbital Mucormycosis

1. Background

2. Established Foundation (context for what's new)

• Antifungals: Mucorales are susceptible to amphotericin B; among azoles, only posaconazole and isavuconazole have reliable in vitro/in vivo activity (echinocandins and other azoles are not effective). Lipid formulations of amphotericin B (liposomal, lipid complex, colloidal dispersion) are preferred for reduced nephrotoxicity - Medical Microbiology, 9th ed.; Goldman-Cecil.
• Isavuconazole has FDA approval for first-line mucormycosis treatment, based on comparative data against amphotericin B-treated historical/registry controls (FungiScope registry comparison) - Fishman's Pulmonary Diseases.
• No survival benefit has been shown for combining posaconazole with another antifungal; isavuconazole plus polyene combination showed benefit only in murine models, not confirmed in humans - Harrison's, 22nd ed.
• Surgical debridement (including orbital exenteration in advanced disease) combined with immune reconstitution/reversal of predisposing factors (correcting ketoacidosis, reducing immunosuppression) remains central to control.

3. Key Recent Advance: Transcutaneous Retrobulbar Amphotericin B (TRAMB)

• Concept: Direct retrobulbar (periocular) injection of amphotericin B delivers high local drug concentration to orbital tissue while limiting systemic nephrotoxicity, used as an adjunct to systemic antifungal therapy rather than a replacement.
• Systematic review evidence (PMID 38772559, 2024, American Journal of Rhinology & Allergy) consolidated existing case series/cohorts on TRAMB for invasive fungal sinusitis with orbital involvement, supporting its role as an emerging adjunctive technique.
• Multicenter retrospective comparative study (PMID 36880205, 2024, Orbit) found that ROCM patients with local orbital involvement treated with adjunctive TRAMB had a lower exenteration rate with no increased mortality risk compared with those managed without it - the key outcome supporting its adoption.
• Long-term outcome data (PMID 36727338, 2023, Indian Journal of Ophthalmology) from the large post-COVID mucormycosis wave describe durable orbital disease control with TRAMB.
• 2026 case reports and cohort data continue to refine technique and indications:
  • A 2026 case report (PMID 41509579) describes TRAMB combined with exenteration in bilateral orbital mucormycosis, illustrating its use even alongside surgery in severe bilateral disease.
  • A 2026 retrospective study (PMID 40739877, European Journal of Ophthalmology) specifically evaluated "orbit management sans exenteration" using retrobulbar amphotericin B injection and its impact on survival - reinforcing that eye/orbit-sparing management does not compromise survival when appropriately selected.
• Related local delivery approaches: intraorbital amphotericin B in an allogeneic HSCT recipient (PMID 38664590, case report) and subcutaneous liposomal amphotericin B for eyelid cutaneous mucormycosis in a pediatric patient (PMID 37995143) demonstrate the broader trend toward localized/targeted amphotericin delivery across mucormycosis presentations, not just classic ROCM.
• A 2025 case report (PMID 40276688) also explored preoperative amphotericin B administration as part of a staged treatment protocol prior to definitive orbital surgery.

4. Evolving Role of Orbital Exenteration

• A 2025 study (PMID 41409565 / PMC12705349) specifically explored the role of orbital exenteration in survival, concluding that globe-sparing orbital exenteration (OE) may serve as a viable alternative for patients with localized, late-stage infection or reversible ROCM risk factors - suggesting a more nuanced, staged surgical approach rather than routine radical exenteration.
• A 2025 study on treatment and survival outcomes (Boqaaiya et al.) found that while exenteration may offer survival benefit in advanced cases, timely medical treatment combined with less invasive surgical approaches can achieve comparable outcomes in appropriately selected patients - reinforcing a shift toward reserving radical exenteration for the most severe, non-responsive cases rather than as first-line management for any orbital involvement.
• This reflects a broader paradigm shift: aggressive early antifungal therapy (systemic + TRAMB) plus limited/staged debridement is increasingly preferred over immediate radical exenteration, provided the disease is localized and the patient's systemic risk factors are correctable.

5. Reconstructive and Rehabilitative Advances

• A 2024 systematic review (PMID 38263556) on prosthetic rehabilitation of intraoral/orbital defects in ROCM patients consolidates approaches to facial/orbital prosthetic reconstruction after radical surgery.
• Total eyelid complex-sparing orbital exenteration techniques (case reports) aim to preserve periocular anatomy for better prosthetic fit and cosmesis when exenteration cannot be avoided.

6. Special Populations and Emerging Presentations

• Pediatric mucormycosis: a 2024 systematic review of pediatric COVID-19-associated cases (PMID 38216422) and a 2025 pediatric intracranial case series/review (PMID 40329649, involving Rhizomucor pusillus) highlight that pediatric ROCM, while rarer, carries distinct risk profiles (often diabetic ketoacidosis-associated) and can present atypically (e.g., stroke-like presentation from intracranial extension).
• Oromaxillofacial and dental-associated mucormycosis: reviews on invasive disease following dental extractions (PMID 36863136) and oromaxillofacial management (PMID 36810012) are relevant where orbital extension arises secondarily from sinonasal/dental disease, reinforcing multidisciplinary (ENT, maxillofacial, ophthalmology, infectious disease) management as standard of care.

Summary of Practical Advances

Evidence Currency Note

Recent Advances in the Management of Dry Eye Disease (DED)

1. Framework and Established Baseline

• Mild: preservative-free artificial tears
• Moderate: increased tear frequency, lubricating gel/ointment at night, lifestyle modification, topical cyclosporine 0.05%/0.09% (often paired with a short pulse of a mild topical steroid like loteprednol to bridge the 1-3 month onset delay), lifitegrast 5% (LFA-1 antagonist, onset ~2 weeks-3 months), punctal occlusion
• Severe: combinations of the above plus permanent punctal occlusion, autologous serum tears, scleral/bandage lenses, tarsorrhaphy in refractory cases - Wills Eye Manual, pp. 174-175; Firestein & Kelley's Rheumatology.

2. Major Practice-Changing Advance: TFOS DEWS III (2025)

3. New FDA-Approved Agents (2023-2025) - Now Established in Practice

4. Device-Based (Meibomian Gland) Advances

• LipiFlow (thermal pulsation): A 2024 Cochrane systematic review (PMID 38314898) and its 2025 summary (PMID 39562261) evaluated evidence for LipiFlow in MGD-related DED - findings show modest, generally low-to-moderate certainty evidence of benefit over warm compress/lid hygiene, tempering earlier enthusiasm.
• TearCare (a thermo-mechanical, wearable eyelid-warming device): the Sahara RCT Stage 3 results (PMID 40719437, 2025) demonstrate durability of treatment effect over extended follow-up, positioning it as a competitor to LipiFlow with potentially more sustained benefit.
• Comparative device data: A 2024 study (PMID 39680541) directly compared a thermo-mechanical action device against a thermal pulsation device for MGD, informing device selection in clinical practice.
• Intense pulsed light (IPL/OptiLight) continues to expand as an in-office option for MGD/ocular rosacea-associated evaporative dry eye, though robust comparative RCT data remain more limited than for thermal pulsation devices.
• Basic science: 2025 work identifying meibomian gland stem cell populations and Hedgehog-pathway-driven aging mechanisms (PMID 39955307, Nature Communications) and new organoid models of MGD (PMID 41533904, 2026) represent foundational research that may eventually enable regenerative approaches to gland dysfunction, though these remain preclinical.

5. Emerging/Pipeline Agents (Not Yet Approved)

• Reproxalap - a RASP (reactive aldehyde species) inhibitor targeting an upstream inflammatory mediator pathway distinct from calcineurin/LFA-1 inhibition; positioned as potentially faster-acting than steroids or existing immunomodulators. As of mid-2026 commentary, it remains pending FDA clearance - a notable near-term addition to watch rather than an established option.
• Quality-controlled/room-temperature-stable autologous serum tears (e.g., processed through standardized programs) are addressing a long-standing practical barrier (frozen storage, compounding variability), expanding accessibility of biologic tear therapy.
• Allogeneic serum tear formulations are in earlier development as a scalable alternative to autologous serum, avoiding the need for each patient's own blood draw.
• Mucin secretagogues: a 2024 randomized crossover trial (PMID 38858411) directly compared two mucin secretagogue agents, reflecting continued interest in restoring the mucin layer of the tear film as a therapeutic target distinct from aqueous or lipid-focused approaches.
• Neuroregenerative and epithelial-repair-targeted agents are described industry-wide (2026 pipeline commentary, Review of Ophthalmology) as a new frontier, alongside lipid-regulating meibomian gland-targeted small molecules - reflecting a shift from purely anti-inflammatory approaches toward mechanism-specific, personalized regimens as envisioned in DEWS III.
• The DelveInsight 2026 Dry Eye Disease Pipeline Report catalogs over 60 pipeline drug candidates across more than 50 companies, indicating this remains one of the most active therapeutic development areas in ophthalmology.

6. Long-Term Natural History Data

7. Notable Negative/Null Findings Worth Knowing

• A 2024 RCT (PMID 38062637) on homeopathic eye drops for mild-to-moderate DED found comparable efficacy to conventional artificial tears in a single-masked equivalence design - relevant mainly for its methodological interest rather than as a treatment recommendation.
• A 2024 RCT on Quantum Molecular Resonance device therapy (PMID 38166187) explored a novel physical-modality approach, but remains investigational with limited corroborating data.

Evidence Currency Note

Severe Dry Eye Disease: Assessment and Management

1. Defining "Severe" Dry Eye

• Persistent symptoms despite maximal conventional therapy (artificial tears, anti-inflammatories, punctal occlusion)
• Significant ocular surface staining (corneal and conjunctival), often with filamentary keratitis
• Risk of vision-threatening complications: epithelial breakdown, sterile corneal ulceration/melt, perforation
• Frequently associated with an identifiable systemic driver, most importantly Sjögren syndrome (primary or secondary) - Kanski's Clinical Ophthalmology, 10th ed., p. 7222-7225, which distinguishes Sjögren-associated dry eye from non-Sjögren aqueous-deficient dry eye as a key branch point in assessment.

1. Level 1 - confirms DED via objective measures: tear film instability, hyperosmolarity, ocular surface damage (staining), and symptoms.
2. Level 2 - identifies the underlying driver(s) (aqueous-deficient, evaporative/MGD, neuropathic, mixed), since DED is now recognized as almost always multifactorial rather than fitting one severity category.

2. Assessment of Severe/Refractory Dry Eye

• Slit-lamp grading of corneal/conjunctival staining (fluorescein, lissamine green), tear break-up time, Schirmer testing
• Point-of-care tear osmolarity and MMP-9 to confirm active inflammatory/hyperosmolar disease - Wills Eye Manual, p. 174
• Tear lactoferrin: low levels support an aqueous-deficient mechanism
• Exclude eyelid malposition, blink abnormality, exposure keratopathy, neurotrophic keratopathy, and limbal stem cell deficiency, all of which mimic or worsen severe DED and require distinct management

• Screen for Sjögren syndrome when dry mouth, arthralgia, or other autoimmune features are present (anti-SSA/SSB, ANA, RF, minor salivary gland biopsy where indicated) - Wills Eye Manual; Firestein & Kelley's Textbook of Rheumatology
• Consider graft-versus-host disease, prior radiation, vitamin A deficiency, and cicatrizing conjunctival disease (e.g., ocular cicatricial pemphigoid, Stevens-Johnson sequelae) as causes of severe aqueous-deficient/cicatricial dry eye
• A 2026 systematic review (PMID 41572466) specifically catalogs DED following ocular or systemic infection (including post-COVID), an increasingly recognized secondary cause worth considering in the history.

• Filamentary keratitis, persistent epithelial defect, sterile ulceration, and impending/actual perforation change management urgency substantially and are addressed by the 2023 Indian Preferred Practice Pattern (PPP) guideline on corneal perforations in dry eye disease (PMID 37026269), which recommends cyanoacrylate tissue adhesive or urgent keratoplasty for perforation, with conjunctival flap or amniotic membrane graft for impending perforation - Wills Eye Manual, p. 5564-5576.

3. Stepwise Management of Severe Dry Eye

1. Preservative-free artificial tears up to q1-2h; lubricating gel/ointment at bedtime; humidification, lid taping if nocturnal lagophthalmos contributes - Wills Eye Manual, p. 3336-3342
2. Topical cyclosporine 0.05%/0.09% or lifitegrast 5%, often started with a bridging pulse of a mild topical steroid (loteprednol, fluorometholone) to offset the 1-3 month delay to effect
3. Punctal occlusion - reversible plugs first; a 2024 systematic review of punctal cautery (PMID 39127391) supports permanent thermal occlusion in patients whose plugs repeatedly extrude, provided any active blepharitis/inflammation is controlled first (uncontrolled inflammation risks epiphora or pyogenic granuloma with permanent occlusion)
4. New pharmacologic option: TRYPTYR (acoltremon ophthalmic solution 0.003%), a TRPM8 cold-thermoreceptor agonist, launched in the US in July 2025 - a novel mechanism that stimulates basal tear production via corneal cold receptors rather than through anti-inflammatory or cholinergic pathways. Positive Phase 3 COMET-2/COMET-3 trials showed statistically significant improvement in tear production, adding a new option specifically for severe aqueous-deficient cases with poor tear production.
5. Miebo (perfluorohexyloctane) for the evaporative/MGD-driven component when present, and Tyrvaya (varenicline nasal spray) for patients wanting a drop-free option (covered in prior notes on general DED advances).

4. Special Situations Relevant to Severe Dry Eye

• Perioperative (cataract/refractive surgery) management: the 2023 PPP on cataract surgery in dry eye disease (PMID 37026268) emphasizes optimizing ocular surface disease before elective surgery, since severe untreated DED significantly worsens postoperative visual outcomes and patient satisfaction - relevant given the "Postoperative dry eye syndrome" entity described in Kanski's (10th ed.).
• Device-based adjuncts (IPL, thermal pulsation/LipiFlow, TearCare) are useful for the evaporative/MGD component that frequently coexists with severe aqueous-deficient disease, but a 2024 meta-analysis of IPL (PMID 38146980) and the Cochrane LipiFlow reviews show only modest, low-to-moderate certainty benefit - these should be considered adjunctive, not primary, therapy in truly severe disease.
• Regional consensus frameworks: the 2024 Taiwan Society of Cataract and Refractive Surgeons consensus (PMID 39075430) offers a practical "bridging the gap" algorithm useful for stepwise escalation decisions in real-world practice, broadly consistent with the AAO PPP and TFOS DEWS III driver-based approach.

Summary Escalation Ladder for Severe DED

Evidence Currency Note

Amblyopia: Management and Recent Advances

1. Definition and Classification

• Strabismic - continued monocular suppression of the deviating eye
• Anisometropic - refractive difference between eyes as small as 1D causes chronic blur in the more ametropic eye; often coexists with microstrabismus
• Stimulus deprivation - unilateral or bilateral, from media opacity (cataract) or ptosis covering the pupil; the most amblyogenic type
• Bilateral ametropic - high symmetric refractive error, usually hypermetropia
• Meridional - uncorrected astigmatism (>1D) persisting beyond the emmetropization period

2. Established Treatment (Foundation)

• Correct organic disease first - fundus exam is mandatory before labeling reduced vision as amblyopia; a trial of patching may still proceed even with coexisting organic disease.
• Sensitive period: up to 7-8 years for strabismic amblyopia; may extend into the teens for anisometropic amblyopia with good underlying binocular function - Kanski's, p. 1522.
• Occlusion (patching) of the sound eye remains the most effective conventional treatment; regimen (full-time vs part-time) depends on age and amblyopia density.
• Atropine penalization of the normal eye is an effective alternative, working best for mild-moderate amblyopia (6/24 or better), especially anisometropic hypermetropic amblyopia - Kanski's, p. 1527; based on the landmark PEDIG ATS1 trial (atropine vs patching, Arch Ophthalmol 2002) which established both as gold-standard options.
• Occlusion amblyopia (iatrogenic amblyopia of the fellow eye from excessive patching/atropine) is a recognized complication requiring monitoring - Wills Eye Manual, p. 2076-2086.
• Continue patching until vision equalizes or plateaus over three compliant cycles; part-time maintenance patching if recurrence risk is high - Wills Eye Manual, p. 2111-2120.
• Optical treatment alone (refractive correction with glasses, without patching) can be effective first-line therapy in many cases, particularly anisometropic amblyopia - a 2024 RCT (PMID 38757545) validated the Occlusion Dose Monitor (ODM) equivalent for measuring spectacle wear compliance and confirmed meaningful improvement from optical correction alone before escalating to occlusion.

3. Major Recent Advance: Dichoptic / Binocular Digital Therapeutics

• Luminopia - a VR headset streaming modified children's television content (regular programming with contrast/luminance manipulation between eyes); FDA-authorized binocular digital therapeutic for ages 4-7. The pivotal RCT (Xiao et al., Ophthalmology 2022) showed significant visual acuity improvement, and a 2024 AJO paper (PMID 38360334) demonstrated that gains were stable at one year of follow-up, addressing durability concerns. Real-world registry data (334 patients) presented at the 2025 American Academy of Optometry meeting further supported effectiveness in severe amblyopia in routine clinical use.
• CureSight (NovaSight) - an eye-tracking-based dichoptic system that selectively blurs the fovea of the dominant eye during natural screen/video viewing (rather than a full VR headset), also FDA-cleared.
• A 2025 multicenter RCT (PMID 39179129, American Journal of Ophthalmology) directly compared high-adherence dichoptic treatment versus patching in anisometropic and small-angle strabismic amblyopia, adding head-to-head efficacy data rather than just placebo-controlled trials.
• A binocular iPad game (Dig Rush) pilot study in 182 children aged 4-6 showed greater amblyopic-eye visual acuity improvement after 4 weeks versus continued spectacle correction alone.
• A 2024 RCT of a novel video game platform (PMID 37092663) further supports gamified binocular approaches as a feasible pediatric treatment modality with good engagement.

4. Adherence - A Persistent Practical Problem, Now Addressed More Directly

5. Other Investigational/Emerging Approaches

• Perceptual learning combined with patching: a 2025 RCT (PMID 39396111) compared vision therapy plus patching, perceptual learning plus patching, and patching alone - suggesting combination approaches may outperform monotherapy, though this needs further replication.
• Fluoxetine for adult amblyopia: a 2024 double-blind placebo-controlled RCT (PMID 39304030) tested fluoxetine (an SSRI hypothesized to enhance visual cortex plasticity) as a pharmacologic adjunct for adult amblyopia - a population traditionally considered largely untreatable once past the sensitive period. This reflects growing interest in pharmacologically extending or reactivating plasticity beyond the classic critical period.
• Transcranial magnetic stimulation (TMS): a 2025 RCT (PMID 40315924) explored TMS-based neuroplasticity induction for amblyopia treatment, another non-pharmacologic approach targeting cortical plasticity directly, again primarily studied in adults/older patients outside the classic pediatric treatment window.
• Both the fluoxetine and TMS approaches remain investigational and are not part of standard pediatric amblyopia management, but represent an important conceptual shift: challenging the assumption that amblyopia is untreatable beyond the pediatric sensitive period.

Summary Treatment Ladder

Evidence Currency Note